MSB
Mesoblast Ltd
Biotechnology
·
Healthcare
4
comments
3
fund managers
past 90 days
About Mesoblast Ltd
Mesoblast Ltd. is an Australian biopharmaceutical company founded in 2004 by Silviu Itescu. Headquartered in Melbourne, the company specializes in researching, developing, and commercializing mesenchymal lineage adult stem cell technology. Its clinical pipeline targets therapeutic solutions for cardiovascular diseases, spine orthopedic disorders, oncology, hematology, and immune-mediated inflammatory diseases.
Commentary Volume
4
Comments
3
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$3B
Fund managers
3 managers
First covered
31 May 2024
Last updated
31 Dec 2024
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Mesoblast Ltd (ASX:MSB)
Frequently asked questions
Who is investing in Mesoblast Ltd (ASX:MSB)?
Fund managers including Blackwattle Investment Partners, Pengana Capital Group and Tyndall Asset Management have invested in Mesoblast Ltd (ASX:MSB).
What is the short interest in Mesoblast Ltd (ASX:MSB)?
The short interest in Mesoblast Ltd (ASX:MSB) is 6.71% which makes it the 28th most shorted stock on the ASX. Of the 1.3B shares that Mesoblast Ltd has on issue, 86.1M have been sold short.
What does Mesoblast Ltd (ASX:MSB) do?
Mesoblast Ltd. is an Australian biopharmaceutical company founded in 2004 by Silviu Itescu. Headquartered in Melbourne, the company specializes in researching, developing, and commercializing mesenchymal lineage adult stem cell technology. Its clinical pipeline targets therapeutic solutions for cardiovascular diseases, spine orthopedic disorders, oncology, hematology, and immune-mediated inflammatory diseases.
Loading...